According to GlobalData’s Pharma Intelligence Center Chinese patent authority is ranked on the top with 16,983 pharmaceutical grants issued so far in H1 2021.
Brukinsa® (zanubrutinib) is under regulatory review for relapsed, refractory MCL in the Russian Federation with potential approval at the end of the 2021.
Nanolek, a biopharmaceutical company, announces a plan to invest 5 billion rubles over 3 years in its full-cycle vaccine production facility in the Kirov region and an R&D Center for Biotech Medicines in Moscow.